Item 3.
Legal Proceedings.
126
Item 4.
Mine Safety Disclosures.
128
PART II
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and 

Issuer Purchases of Equity Securities.
129
Item 6.
Reserved.
130
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations.
131
Item 7A.
Quantitative and Qualitative Disclosures About Market Risk.
154
Item 8.
Financial Statements and Supplementary Data.
156
Item 9.
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.
230
Item 9A.
Controls and Procedures.
230
Item 9B.
Other Information.
233
Item 9C.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
233
PART III
Item 10.
Directors, Executive Officers and Corporate Governance.
234
Item 11.
Executive Compensation.
234
Item 12.
Security Ownership of Certain Beneficial Owners and Management and 

Related Stockholder Matters.
234
Item 13.
Certain Relationships and Related Transactions, and Director Independence.
234
Item 14.
Principal Accountant Fees and Services.
234
PART IV
Item 15.
Exhibits and Financial Statement Schedules.
235
Item 16.
Form 10-K Summary.
240
Signatures
241
Defined Terms
Unless expressly indicated or the context required otherwise, the terms “ImmunityBio,” “the company,” “we,” “us,” and “our” in this Annual Report refer to ImmunityBio, Inc., a Delaware corporation, and, where appropriate, its subsidiaries. We have also used several other terms in this Annual Report, the consolidated financial statements and accompanying notes included herein, most of which are defined below:
Term
Definition
2014 Plan
NantKwest, Inc. 2014 Equity Incentive Plan
2015 Plan
ImmunityBio, Inc. 2015 Equity Incentive Plan
2015 Share Repurchase Program
Board of Directors-approved share repurchase program 
3M IPC
3M Innovative Properties Company
3PL Agent
logistics agent
401(k) Plan
401(k) retirement and savings plan
AAHI
Access to Advanced Health Institute
ACA
Affordable Care Act
ADCC
antibody-dependent cellular cytotoxicity
ALC
absolute lymphocyte count
Altor
Altor BioScience, LLC
America Invents Act
Leahy-Smith America Invents Act
Amyris
Amyris, Inc.
ANC
absolute neutrophil count
aNK
activated NK cells
ANKTIVA
®
Proprietary name for N-803 (formerly ALT-803), our novel IL-15 receptor superagonist 
   complex (nogapendekin alfa inbakicept-pmln) currently approved for use in the 
   United States with BCG for the treatment of adult patients with BCG-unresponsive 
   non-muscle invasive bladder cancer with carcinoma 
in situ
 with or without papillary tumors, 
   and currently in clinical development for other indications.
Annual Report
Annual Report on Form 10-K for the year ended December 31, 2024
Approved product
ANKTIVA
ART
anti-retroviral therapy
ASC
Accounting Standards Codification
ASCO
American Society of Clinical Oncology
ASU
Accounting Standards Update
Athenex
Athenex, Inc.
ATM
“at-the-market” sales agreement
ATRA
American Taxpayer Relief Act of 2012
BCG
Bacillus Calmette-Guérin (TICE
®
 BCG approved for use in the U.S.)
Beike
Shenzhen Beike Biotechnology Co. Ltd.
BLA
Biologics License Application
bNAbs
broadly-neutralizing antibodies
BPCIA
Biologics Price Competition and Innovation Act of 2009
Brink
Brink Biologics, Inc.
Cambridge
Cambridge Equities, LP
CAR
chimeric antigen receptor
CCPA
California Consumer Privacy Act of 2018
CEO
chief executive officer
i
Term
Definition
CFO
chief financial officer
cGMP
current Good Manufacturing Practice
China
when used in connection with the RIPA, People’s Republic of China, Hong Kong and any 
   territories controlled by the People’s Republic of China
CI
confidence interval
CIO
chief information officer
CIS
carcinoma 
in situ
Clinic
Immuno-Oncology Clinic, Inc.
Closing Date
when used in connection with the RIPA, December 29, 2023
CMC
Chemistry, Manufacturing and Controls
CMO
contract manufacturing organization
CMS
Centers for Medicare & Medicaid Services
Code
Internal Revenue Code of 1986, as amended
CODM
chief operating decision maker
CPI
checkpoint inhibitor
CPRA
California Privacy Rights Act
CR
complete response
CRADA
Cooperative Research and Development Agreement
CRL
complete response letter
CRO
contract research organization
CVR
contingent value right
DAMPs
damage-associated molecular patterns
DGCL
Delaware General Corporation Law
DOD
U.S. Department of Defense
DSCSA
Drug Supply Chain Security Act
Duley Road
Duley Road, LLC
Dunkirk Facility
a leasehold interest in a cGMP ISO Class 5 pharmaceutical manufacturing space in 
   western New York
EAP
Expanded Access Program
EEA
European Economic Area
EGFR
epidermal growth factor receptor
EMA
European Medicines Agency
ERM
Enterprise Risk Management
EU
European Union
Exchange Act
Securities Exchange Act of 1934, as amended
Exyte
Exyte U.S., Inc.
FASB
Financial Accounting Standards Board
FCA
False Claims Act
FCPA
U.S. Foreign Corrupt Practices Act
FD&C Act
Federal Food, Drug, and Cosmetic Act
FDA
U.S. Food and Drug Administration
FDASIA
Food and Drug Administration Safety and Innovation Act of 2012
FIFO
First In First Out inventory method
ii
Term
Definition
FSMC
Fort Schuyler Management Corporation, a not-for-profit corporation affiliated with the 
   State of New York
FTC
Federal Trade Commission
FTO
freedom-to-operate
FVO
fair value option
GBM
glioblastoma multiforme
GCP
Good Clinical Practice
GDPR
General Data Protection Regulation
GlobeImmune
GlobeImmune, Inc.
GLP
Good Laboratory Practice
GMP
Good Manufacturing Practice
hAd5
human adenovirus serotype 5
haNK
high-affinity NK
Hatch-Waxman Act
Drug Price Competition and Patent Term Restoration Act of 1984
HCPCS
Healthcare Common Procedure Coding System, a set of standardized codes used in the U.S.
   to describe specific medical procedures, services, equipment, medications, and supplies.
HCW
HCW Biologics, Inc.
HHS
U.S. Department of Health and Human Services
HIPAA
Health Insurance Portability and Accountability Act of 1996
HITECH
Health Information Technology for Economic and Clinical Health Act
HIV
human immunodeficiency virus
IDE
Investigational Device Exemption
IgDraSol
IgDraSol, Inc., a subsidiary of the company
IL-15
novel interleukin 15
IND
investigational new drug
Infinity
Infinity SA LLC, as purchaser agent for affiliates of Oberland
iNHL
indolent non-Hodgkin lymphoma
IPR&D
In-process research and development
IRA
Inflation Reduction Act of 2022
IRB
Institutional review boards
IRS
Internal Revenue Service
J-code
a part of the HCPCS used to designate non-oral medications and other medical devices
LDMC
low-dose metronomic chemotherapy
LMIC
low- and middle-income countries
M-ceNK
memory-like cytokine-enhanced NK
MAA
Marketing Authorization Application
mAbs
monoclonal antibodies
MCC
Merkel cell carcinoma
mCRCP
metastatic castration-resistant prostate cancer
MDSC
myeloid-derived suppressor cells
MHC
major histocompatability complex
MHC-I
major histocompatability complex class I
MHC-II
major histocompatability complex class II
iii
Term
Definition
MHRA
Medicines and Healthcare products Regulatory Agency
MTD
maximum tolerated dose
NAI
nogapendekin alfa inbakicept-pmln
NantBio
NantBio, Inc.
Nant Capital
Nant Capital, LLC
NantCell
NantCell, Inc., a subsidiary of the company
NANTibody
Immunotherapy NANTibody, LLC, a subsidiary of the company
NantKwest
NantKwest, Inc.
NantMobile
NantMobile, LLC
NantPharma
NantPharma, LLC
NantWorks
NantWorks, LLC, a related party
NC 2015 Plan
NantCell, Inc. 2015 Stock Incentive Plan
NCI
National Cancer Institute
NCV
Nant Cancer Vaccine
NEO
named executive officer
NHL
non-Hodgkin lymphoma
NIAID
National Institute of Allergy and Infectious Diseases
NIH
National Institutes of Health
NIH Guidelines
NIH Guidelines for Research Involving Recombinant DNA Molecules
NK
natural killer
NMIBC
non-muscle invasive bladder cancer
NOL
net operating loss
NSCLC
non-small cell lung cancer
OBA
NIH Office of Biotechnology Activities
Oberland
Oberland Capital Management LLC and its affiliates (including Purchasers as 
   defined in the RIPA)
OFAC
U.S. Treasury Department’s Office of Foreign Assets Control
PCAOB
Public Company Accounting Oversight Board (United States)
PD-1
programmed death receptor 1
PD-L1
programmed death receptor ligand
PDMA
U.S. Prescription Drug Marketing Act
PHI
Protected Health Information
PHSA
Public Health Service Act
PMA
premarket approval
PREA
Pediatric Research Equity Act
PRO
Patient Recorded Outcomes
Proxy Statement
Schedule 14A in connection with our 2025 Annual Meeting of Stockholders
PSA
prostate-specific antigen
QMSR
Quality Management System Regulation
QSR
Quality System Regulation
QUILT
QUantum Integrative Lifelong Trial
R&E
research and experimental expenditures
RAC
Recombinant DNA Advisory Committee
iv
Term
Definition
rBCG
recombinant BCG
RDO
registered direct offering
RBCs
red blood cells
RECIST
response evaluation criteria in solid tumors
REMS
Risk Evaluation and Mitigation Strategy
RIPA
Revenue Interest Purchase Agreement
Riptide
Riptide Bioscience, Inc.
RMAT
regenerative medicine advanced therapy
RSU
restricted stock unit
SAFE
Simple Agreement for Future Equity
Sarbanes-Oxley
Sarbanes-Oxley Act of 2002
SARS-CoV-2
novel strain of the coronavirus (COVID-19)
sBLA
supplemental Biologics License Application
SEC
U.S. Securities and Exchange Commission
Section 404
Section 404 of the Sarbanes-Oxley Act of 2002
Securities Act
Securities Act of 1933, as amended
Serum Institute
Serum Institute of India Private Limited
Sorrento
Sorrento Therapeutics, Inc.
SPOA
Stock Purchase and Option Agreement 
SQ
subcutaneous
SRLY
separate return limitation year
TAA
tumor-associated antigen
TCJA
Tax Cuts and Jobs Act of 2017
Term SOFR
Term Secured Overnight Financing Rate
Test Date
when used in connection with the RIPA, December 31, 2029
TF Platform
tissue factor-based fusion discovery platform
TGF-β
transforming growth factor beta
t-haNK
targeted high-affinity NK
TLR
toll-like receptor
TME
tumor microenvironment
TNBC
triple-negative breast cancer
T-reg
regulatory T cells
TriAd
Triple Antigen (CEA, MUC1, Brachyury)
UK
United Kingdom
UK GDPR
UK Data Protection Act of 2018
U.S. GAAP
accounting principles generally accepted in the United States of America
USPTO
U.S. Patent and Trademark Office
VA
Veterans Affairs
VBC Holdings
VBC Holdings, LLC, a subsidiary of the company
VIE
variable interest entity
VivaBioCell
VivaBioCell, S.p.A., a wholly-owned subsidiary of VBC Holdings
v
Table of Conten
t
s
PART I